Vertex Pharmaceuticals (VRTX)
NASDAQ: VRTX
· Real-Time Price · USD
498.44
-11.06 (-2.17%)
At close: May 01, 2025, 3:59 PM
502.99
0.91%
After-hours: May 01, 2025, 07:02 PM EDT
Vertex Pharmaceuticals Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRIKAFTA/KAFTRIO Revenue | 2.58B | 2.45B | 2.48B | 2.33B | 2.27B | 2.24B | 2.1B | 2.02B | 2.01B | 1.89B | 1.76B | 1.69B | 1.56B | 1.26B | 1.19B | 960.31M | 917.72M | 895.23M |
| TRIKAFTA/KAFTRIO Revenue Growth | +5.54% | -1.39% | +6.44% | +2.59% | +1.51% | +6.85% | +3.72% | +0.55% | +6.20% | +7.47% | +4.08% | +8.79% | +23.91% | +5.23% | +24.25% | +4.64% | +2.51% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 3.11B | 2.71B | 1.97B | 1.13B | 885.76M | 543.18M | 420.32M | 320.46M | 219.6M | 197.61M | 279.56M | 1.37B | 1.39B |
| Europe Revenue Growth | +14.91% | +37.13% | +75.14% | +27.17% | +63.07% | +29.23% | +31.16% | +45.93% | +11.13% | -29.31% | -79.65% | -1.16% | n/a |
| Non-Us Revenue | 4.55B | 3.76B | 2.6B | 1.63B | 1.31B | 821.86M | 501.87M | 380.37M | 269.02M | 219.34M | 315.02M | n/a | n/a |
| Non-Us Revenue Growth | +21.06% | +44.55% | +59.82% | +23.70% | +59.98% | +63.76% | +31.94% | +41.39% | +22.65% | -30.37% | n/a | n/a | n/a |
| United States Revenue | 6.04B | 5.7B | 5.29B | 4.83B | 3.06B | 2.37B | 1.99B | 1.32B | 763.32M | 361.07M | 896.95M | n/a | n/a |
| United States Revenue Growth | +5.98% | +7.79% | +9.48% | +57.69% | +29.49% | +19.04% | +50.31% | +73.17% | +111.40% | -59.74% | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 377.6M | 371.8M | 372.2M | 342.7M | 369.1M | 263.8M | 262.6M | 241.1M | 267.4M | 246.8M | 215.3M | 215.2M | 255.2M | 198.19M | 194.67M | 192.08M | 211.84M | 184.55M | 191.8M | 182.26M | 195.28M | 159.67M | 156.5M | 147.04M | 153.21M | 137.29M | 137.3M | 129.81M | 134.79M | 120.71M | 127.25M | 113.33M | 109.91M | 106.06M | 111.65M | 105.21M | 97.05M | 99.77M | 94.39M | 85.86M |
| Selling, General, and Administrative Revenue Growth | +1.56% | -0.11% | +8.61% | -7.15% | +39.92% | +0.46% | +8.92% | -9.84% | +8.35% | +14.63% | +0.05% | -15.67% | +28.77% | +1.81% | +1.35% | -9.33% | +14.79% | -3.78% | +5.24% | -6.67% | +22.30% | +2.03% | +6.43% | -4.02% | +11.59% | -0.01% | +5.77% | -3.70% | +11.67% | -5.14% | +12.29% | +3.11% | +3.63% | -5.01% | +6.12% | +8.41% | -2.72% | +5.70% | +9.94% | n/a |
| Research and Development Revenue | 998.7M | 875.9M | 5.42B | 865.9M | 821.8M | 810M | 785.7M | 742.6M | 694.1M | 645M | 600.1M | 603.1M | 694.3M | 493.75M | 1.41B | 455.97M | 466.58M | 493.5M | 420.93M | 448.53M | 480.01M | 555.95M | 379.09M | 339.49M | 437.88M | 330.51M | 337.53M | 310.55M | 306.66M | 454.95M | 289.45M | 273.56M | 248.45M | 275.37M | 271.01M | 255.86M | 310.43M | 246.28M | 223.86M | 215.6M |
| Research and Development Revenue Growth | +14.02% | -83.83% | +525.44% | +5.37% | +1.46% | +3.09% | +5.80% | +6.99% | +7.61% | +7.48% | -0.50% | -13.14% | +40.62% | -64.91% | +208.59% | -2.27% | -5.45% | +17.24% | -6.15% | -6.56% | -13.66% | +46.65% | +11.66% | -22.47% | +32.49% | -2.08% | +8.69% | +1.27% | -32.59% | +57.18% | +5.81% | +10.11% | -9.78% | +1.61% | +5.92% | -17.58% | +26.05% | +10.02% | +3.83% | n/a |